These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 35575164)

  • 1. Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life.
    Korde R; Veluswamy R; Allaire JC; Barnes G
    Curr Med Res Opin; 2022 Aug; 38(8):1361-1368. PubMed ID: 35575164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
    Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
    Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
    Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
    Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
    BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
    Wang T; Li Y; Zheng X
    BMC Health Serv Res; 2023 Jun; 23(1):691. PubMed ID: 37365540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
    Chen J; Wang J; Xu H
    Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
    Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
    Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
    Du J; Wang X; Fan L; Shan X; Li M; Liu L
    Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
    Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q
    BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
    Zhou F; Zhao W; Gong X; Ren S; Su C; Jiang T; Zhou C
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
    Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
    Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies.
    Luo H; Song G; Wang D; Li M; Dai N
    Front Immunol; 2022; 13():1059557. PubMed ID: 36544769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.
    Yang C; Xuan T; Gong Q; Dai X; Wang C; Zhang R; Zhao W; Wang J; Yue W; Li J
    Thorac Cancer; 2024 May; 15(15):1246-1262. PubMed ID: 38623838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis.
    Wang S; Li Y; Liu Z; Tian W; Zeng Y; Liu J; Zhang S; Peng Y; Wu F
    Lung Cancer; 2023 Apr; 178():47-56. PubMed ID: 36774774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
    Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
    J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
    Chen C; Tian P; Zhong J; Fan X
    Front Oncol; 2023; 13():1151769. PubMed ID: 37152041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a meta-analysis based on mixed-effect models.
    Zheng J; Deng Y; Huang B; Chen X
    Front Med (Lausanne); 2023; 10():1198950. PubMed ID: 37583422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer.
    Mi S; Yang Y; Liu X; Tang S; Liang N; Sun J; Liu C; Ren Q; Lu J; Hu P; Zhang J
    Clin Transl Oncol; 2024 Sep; 26(9):2339-2350. PubMed ID: 38598001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
    BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.